MedTrace Logo

ECM and Blood Components for Wound Healing

NCT01909908 · Status: TERMINATED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 2

Last updated 2016-09-29

No results posted yet for this study

Summary

The Extracellular Matrix (ECM) and Blood Components for Wound Healing feasibility study is a clinical trial approved by Health Canada to study the safety of extracellular matrix (ECM) and autologous blood products in wound healing.

Conditions

  • Ulcer
  • Venous Ulcer
  • Foot Ulcer, Diabetic

Interventions

DEVICE

ECM

ECM in saline applied to wound

BIOLOGICAL

Blood Products

Autologous blood product applied to wound, with saline cleanse on alternating weeks

DEVICE

ECM in Blood Products

Alternating treatments of ECM in saline and ECM in autologous blood products, applied to wound

Sponsors & Collaborators

  • Cook Group Incorporated

    lead INDUSTRY

Principal Investigators

  • John Embil, MD, FRCPC · University of Manitoba

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-02-28
Primary Completion
2016-06-30
Completion
2016-09-30

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01909908 on ClinicalTrials.gov